Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[192Ir brachytherapy]

T Inoue1, T Inoue, H Yamazaki

  • 1Dept. of Radiation Oncology, Osaka University Medical School, Suita, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of an initial step of T cell adhesion to endothelial monolayers under flow conditions.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria.

Cell·1994
Same author

Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia.

The Journal of urology·1994
Same author

Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes.

Biochemical pharmacology·1994
Same author

Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes.

Blood·1994
Same author

Alternative splicing in the alpha 5(IV) collagen gene in human kidney and skin tissues.

Nihon Jinzo Gakkai shi·1994

High-dose-rate (HDR) brachytherapy using Iridium-192 (Ir-192) shows comparable early outcomes to low-dose-rate (LDR) brachytherapy for oral cancer. HDR brachytherapy enhances patient care and safety in cancer treatment.

Area of Science:

  • Oncology
  • Medical Physics
  • Radiation Therapy

Context:

  • Transition from Radium-226 (Ra-226) to Iridium-192 (Ir-192) manual afterloading in 1973.
  • Implementation of microSelectron-HDR (Ir-192 micro-source) at Osaka University Hospital in 1991.
  • Advancements in brachytherapy techniques driven by modern high technology.

Purpose:

  • To evaluate the efficacy and safety of high-dose-rate (HDR) interstitial brachytherapy compared to low-dose-rate (LDR) brachytherapy for oral cancer.
  • To minimize radiation exposure for hospital personnel involved in brachytherapy procedures.
  • To expand indications and develop new technologies for HDR brachytherapy to improve local cancer cure.

Summary:

  • Preliminary Phase I/II study indicated no significant difference in acute mucosal reactions or early tumor response between HDR and LDR interstitial brachytherapy for oral cancer.

Related Experiment Videos

  • A Phase III study initiated in April 1992 focuses on eliminating radiation exposure risks for personnel.
  • Introduction of remote afterloading for Ir-192 micro-sources has improved care for elderly patients undergoing interstitial brachytherapy for malignancies.

    • Impact:

    • Expanded indications for HDR brachytherapy, including novel techniques like the linked double button for oral cancer and template interstitial brachytherapy for perineal cancer.
    • Development of postoperative brachytherapy strategies for unresectable or microscopically residual disease using intraoperative flexible catheter placement.
    • HDR interstitial brachytherapy is poised to become a viable alternative to traditional LDR interstitial brachytherapy.